GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (2)
Material
Publisher
  • American Association for Cancer Research (AACR)  (2)
Language
Years
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 19_Supplement ( 2014-10-01), p. 3574-3574
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 3574-3574
    Abstract: The rapid advancement in Next Generation Sequencing (NGS) technology has allowed extensive genetic profiling and analysis of tumor tissues. While accurate tumor characterization is crucial for cancer therapy, current sequencing methods are unable to resolve the genetic differences between the heterogeneous cell populations within tumor. By profiling specific subpopulations of cells from a larger heterogeneous population, single cell sequencing can improve the efficiency of cancer treatments through early detection of rare tumor cells, monitoring of circulating tumor cells, and accurate profiling of intra-tumor heterogeneity. In this study, we compared commercially available single cell amplification methods and sequencing platforms for whole genome and whole transcriptome sequencing. We isolated single cells from a human breast cancer cell line, MCF7, and human embryonic kidney cell line, HEK293, by micromanipulation, and their whole genome and transcriptome were sequenced. For whole genome sequencing, the performance of Repli-g (Qiagen), Ampli1 (Slicon Biosystems) and WGA4 (Sigma) were assessed for whole genome amplification. Next, we used TruSeq DNA Library Kit and Ion Plus Fragment Library Kit for library preparation, and whole genome sequencing was performed on HiSeq2000 and Proton. The sequencing data were analyzed by SAMtools/GATK and tmap-f3. For whole transcriptome sequencing, cDNA was synthesized from single cells using SMARTer ultra low input RNA kit (Clontech), and the cDNA library was prepared with Nextera XT library prep kit (Illumina) and Ion Total RNA-Seq Kit v2 (Life Technologies). Sequencing was performed on HiSeq2000 and Proton, and analyzed with Tophat and Cufflink. We show that the percentage of mappable reads and regions with more than 1X coverage in whole genome sequencing were similar to that of the genomic DNA data, but the coverage rate of regions with more than 10X was lower in single cell data on both NGS platforms. In the RNA-Seq, the gene detection rate in single cell and more than 100 cells were about 65% and 85% compare to total RNA, respectively. Citation Format: Nak-Jung Kwon, Woo Chung Lee, Jiwoong Kim, Hyeri Kim, Ahreum Seong, Bong Cho Kim, Doo Hyun Park, Kap-Seok Yang. Analysis of whole genome and transcriptome sequencing in single cell. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3574. doi:10.1158/1538-7445.AM2014-3574
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 3292-3292
    Abstract: Oncolytic virotherapy is a new modality of immunotherapy using spontaneously occurring or genetically engineered viruses to selectively replicate in and kill cancer cells, no harming normal cells. Currently, various oncolytic herpes simplex virus (oHSVs) with enhanced tumor targeting, antitumor efficacy, and safety have been explored in many different models, and on a range of tumor targets. It has been a difficult task to completely retarget HSV to cancer-specific antigens at the plasma membrane of selected tumors, while maintaining the fully lytic potential of HSV. This approach achieved by a deep knowledge of virus natural receptor recognition, binding, and entry mechanisms. Two strategies have been employed including the incorporation of single-chain antibodies (scFv) into gD, gC or gH and the use of soluble adapter molecules that are capable of binding to both HSV and the specific receptor on the target cell. In the previous study, we first reported that HSV could retarget to gastric carcinoma cells by HVEM-CEA adapter molecule. Although we have been shown reasonable efficiency of retargeted cell transduction in vitro and in vivo, it required purification of the adapter protein and continuous addition to the virus prior to infection. To overcome the limitations of adapter molecules, we developed a self-retargeting system by incorporation of adapter expression cassette into the HSV genome that enables the sustained secretion of adapter protein while the viral replication in infected tumor cells. Furthermore, to strengthen the retargeting modality, we constructed a novel, double targeted oHSV, carries no deletion/attenuation, consisting of self-retargeting adapter and modified gH to EpCAM. Our results show that the initial infection and subsequent viral spread depend on cellular EpCAM expression. When injected intravenously (i.v.), they caused no harm to tumor-free mice up to the maximum tested dosage (2 x 108 PFU). When a single intratumoral dose of double targeting oHSV (2 x 106 infectious units) were administered in a xenograft model they rendered 80% of mice tumor-free. Our findings suggest that the double retargeting platform of HSV carrying self-retargeting adapter and modified gH may be potent in cancer-specific cell killing and thus useful for the treatment of EpCAM expressing various cancers. Citation Format: Hyunjung Baek, Hyun-Yoo Joo, Eun-Ran Park, Chun-Seob Ahn, Sujung Lee, Hyeri Kim, Mihee Han, Bora Kim, Heechung Kwon. Double targeting oncolytic herpes simplex virus type 1 (oHSV-1) exhibits effective antitumor activity against EpCAM-expressing cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3292.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...